Bioxcel Therapeutics Logo
Previous slide
Next slide

Our AI-based approach is designed to:

  • Enhance R&D efficiencies
  • Shorten development timelines
  • Increase probability of success

Latest News

VIEW ALL NEWS
Sep 19, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationVIEW RELEASE
Sep 05, 2024
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Aug 07, 2024
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth ConferenceVIEW RELEASE
VIEW ALL NEWS

Stock Information

BioXcel Therapeutics, Inc.

Oct 07, 2024 03:53 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

0.5492

CHANGE

-0.0356 (-6.09%)
EVENTS
SIGN UP FOR EMAIL ALERTS
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2024 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

All other trademarks are the properties of their respective owners.
Copyright © 2023 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.